Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Are there Clinical Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer_ [360p]
